You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,703,787

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,703,787 protect, and when does it expire?

Patent 8,703,787 protects ZYKADIA and is included in two NDAs.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 8,703,787

Patent landscape, scope, and claims:

Title:	Methods of using ALK inhibitors
Abstract:	The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK.sup.+ mediated condition such as EML4-ALK.sup.+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined above.
Inventor(s):	Li; Nanxin (San Diego, CA), Harris; Jennifer Leslie (San Diego, CA), McNamara; Peter (San Diego, CA), Sun; Fangxian (Melrose, MA)
Assignee:	IRM LLC (Hamilton, BM)
Application Number:	13/981,046
Patent Claim Types: see list of patent claims	Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,703,787

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	8,703,787	⤷ Subscribe				TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)	⤷ Subscribe
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	8,703,787	⤷ Subscribe				TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,703,787

PCT Information
PCT Filed	February 02, 2012	PCT Application Number:	PCT/US2012/023669
PCT Publication Date:	August 09, 2012	PCT Publication Number:	WO2012/106540

International Family Members for US Patent 8,703,787

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012212142	⤷ Subscribe
Brazil	112013019643	⤷ Subscribe
Canada	2824092	⤷ Subscribe
China	103458881	⤷ Subscribe
Cyprus	1116662	⤷ Subscribe
Denmark	2670401	⤷ Subscribe
Eurasian Patent Organization	023404	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.